

United States Senate

WASHINGTON, DC 20510

October 3, 2025

Dr. Albert Bourla
Chairman and Chief Executive Officer
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001

Dear Dr. Bourla,

I write to request clarity regarding Pfizer's recently announced agreement with the Trump Administration to implement Most Favored Nation (MFN) pricing in Medicaid and launch a new drug purchasing platform, TrumpRx.gov. To date, few details about this deal have been made public. While the White House touted the agreement as a win for patients, neither the Administration nor Pfizer has disclosed which drugs are covered, what prices have been agreed to, or how patients will benefit. A press release from Pfizer stated that the "specific terms of the agreement remain confidential," which raises serious concerns about this arrangement.¹ Given the importance of this issue to patients, I request you promptly provide answers to the following questions:

1. Which countries and pricing metrics will be used in the MFN formula? CMS officials have referenced a "basket" of wealthy countries from which the lowest net price will be used as a "starting point" for setting U.S. prices under the MFN model. Which specific countries will Pfizer use as comparators, and will the pricing be based on list prices, net prices after rebates/discounts, or some other metric?
2. Will Pfizer commit to transparency in how MFN prices are calculated, and disclose how the final MFN price is calculated, including whether discounts, rebates, or pricing agreements are incorporated?
3. How frequently will MFN comparator pricing be updated? Will changes be made automatically as international pricing data changes?
4. What is the full scope of drugs subject to MFN pricing in Medicaid? The Trump Administration has stated that "virtually all" Pfizer drugs will be covered. Will Pfizer publish a complete list of products included in the agreement?

¹<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaches-landmark-agreement-us-government-lower-drug>

5. Will Pfizer commit to not shifting costs to other markets? Do you commit to not recoup revenue reductions in Medicaid by raising prices in private insurance markets, employer-sponsored plans, or Medicare?
6. Are there plans for Pfizer to expand MFN or TrumpRx-style pricing to the commercial insurance or Medicare Part D markets?

In addition to the MFN arrangement, I request clarification on Pfizer's participation in the TrumpRx platform. As currently described, this model would require patients to bypass their insurance and pay cash for medications — often at high out-of-pocket costs. Given that many insured patients already have lower copays or coinsurance than the proposed TrumpRx discounts, it is unclear how this platform would provide meaningful relief. In fact, it may increase costs for patients.

The lack of transparency surrounding this arrangement raises serious concern. I urge you to make the details of this agreement public and to promptly respond to the questions above.

Sincerely,

A handwritten signature in black ink, reading "Ruben Gallego". The signature is written in a cursive, flowing style with a large initial "R".

Ruben Gallego
United States Senator